NEW YORK — Edgewise Therapeutics Inc. (NASDAQ: EWTX) shares surged more than 23% Tuesday morning, climbing to around $38.83 as investors piled into the clinical-stage biotech company amid growing optimism over its muscle disease pipeline and broader sector momentum.
Edgewise Therapeutics (EWTX) Explodes 23% on Pipeline Momentum and Strong Biotech Sentiment
The stock, which closed Monday near $31.45, jumped as much as 23.47% in early trading on elevated volume. The sharp move pushed Edgewise’s market capitalization higher and marked one of the biggest percentage gains among Nasdaq-listed biotechs on the day.
Edgewise develops novel therapies for serious muscle disorders, including muscular dystrophies and certain cardiac conditions. Its lead candidate, sevasemten, targets skeletal muscle conditions like Becker muscular dystrophy, while EDG-7500 focuses on hypertrophic cardiomyopathy (HCM). Positive long-term data and upcoming catalysts have fueled recent enthusiasm.
Pipeline Progress Fuels Rally
In March 2026, the company reported encouraging long-term results for sevasemten, showing sustained functional stabilization in Becker muscular dystrophy patients over 3.5 years of follow-up. The data reinforced confidence in the program as it advances toward pivotal readouts later this year.
Advertisement
Analysts have highlighted upcoming milestones, including top-line data from the GRAND CANYON pivotal cohort expected in the fourth quarter of 2026. Positive interim safety results from the EDG-7500 program in HCM have also supported sentiment, with some viewing the asset as a potential standout in the cardiac space.
The company recently granted inducement stock options to new employees, a routine move that signals continued hiring and expansion as it prepares for key clinical and regulatory steps.
Analyst Optimism
Wall Street maintains a generally bullish stance on Edgewise. Consensus ratings lean toward Buy, with average price targets around $39, implying further upside from current levels. Some firms have highlighted the company’s focused approach to muscle science and potential first-in-class therapies as key differentiators.
Advertisement
The biotech sector has shown selective strength in 2026, with investors rewarding companies that deliver clear clinical progress amid a cautious overall market. Edgewise’s recent 52-week highs and steady volume spikes reflect growing institutional interest.
Company Background and Strategy
Founded with a singular focus on muscle biology, Edgewise has built a pipeline addressing significant unmet needs. Becker and Duchenne muscular dystrophies affect thousands, with limited treatment options. Its cardiac programs target hypertrophic cardiomyopathy, a condition impacting heart function in broader populations.
The company maintains a strong cash position following prior financings, providing runway through key data readouts. Management has emphasized disciplined execution and strategic partnerships as it advances toward potential commercialization.
Advertisement
Risks and Considerations
As with most clinical-stage biotechs, Edgewise carries risks including clinical trial setbacks, regulatory hurdles and competition from larger players. The stock remains volatile and sensitive to news flow. Upcoming earnings, expected around May 7, will offer further insight into financial health and pipeline spending.
Valuation has expanded with the recent run, prompting some caution around near-term pullbacks. However, many long-term investors view current levels as justified by the potential of its differentiated muscle-focused platform.
Broader Implications
Advertisement
Tuesday’s surge underscores investor appetite for innovative biotech stories with near-term catalysts. As the sector navigates a complex funding and regulatory environment, companies like Edgewise that demonstrate tangible progress in rare diseases can stand out.
For retail and institutional investors alike, the move highlights the importance of monitoring clinical updates and analyst commentary. While volatility is inherent, successful execution on upcoming milestones could drive further upside in the months ahead.
Edgewise Therapeutics continues positioning itself as a leader in precision muscle medicine. With a focused pipeline, strong scientific foundation and supportive market backdrop, the company’s recent performance reflects growing confidence in its ability to deliver meaningful therapies for patients with limited options.
As trading continues, all eyes remain on volume trends, any follow-on news and broader biotech sector dynamics. The substantial gain on Tuesday adds to Edgewise’s momentum heading into a potentially transformative period for the company and its shareholders.
Bristol firm specialises in complex work for renewable energy and storage sectors
HV Energy co-founder and managing director, Craig Steven, left, and co-founder and technical director Louis Wright(Image: RSK)
A Bristol high-voltage power specialist has been acquired by Cheshire engineering group RSK as it looks to grow its integrated services in the renewable energy and energy storage sectors.
HV Energy Systems (HVES) delivers high-voltage grid connection infrastructure projects across the UK, focusing on technically complex high voltage (33kV – 132kV) and extra high voltage (up to 400kV) connections. Its clients include leading UK renewable energy developers and engineering, procurement and construction businesses.
Its 24-strong team specialises in building modularised and containerised substation solutions, so key project elements can be built and tested off-site to help speed up construction projects.
HVES managing director Craig Steven and technical director Louis Wright founded the business and will continue to lead it. In a joint statement, they said: “We are excited to be joining RSK Group. This partnership will strengthen the service and support we deliver to clients, backed by increased scale and access to a wider network. For clients and colleagues, it is business as usual: you will continue to work with the same team and receive the same level of service, underpinned by the trusted relationships we have built.”
Advertisement
RSK Group chief executive officer Alan Ryder said: “The highly skilled HVES team will add significant value to RSK’s energy transition services and we are very pleased to have them join the group and work alongside some outstanding multidisciplinary colleagues on a range of important energy projects.
RSK Group Founder and CEO Alan Ryder(Image: RSK)
“HVES’s capability is particularly valued by renewable energy developers, for whom grid connection is both technically complex and schedule-critical. Delays to energisation can materially affect projects, increasing the importance of delivery certainty and proven technical capability. This makes the HVES team a crucial element in the success of projects that contribute greatly to UK energy security.”
HV Energy Systems was advised by FRP Advisory (corporate finance) and Osborne Clarke (legal).
In 2024, RSK acquired Kendall Kingscott, which has offices in Bristol, Exeter, Cardiff, St Austell, Ringwood and Teddington, and employs more than 200 staff.
| Revenue of $109.23M (21.40% Y/Y) beats by $12.28M
BRC Inc. (BRCC) Q1 2026 Earnings Call May 5, 2026 8:30 AM EDT
Company Participants
Matthew McGinley – Vice President of Investor Relations Chris Mondzelewski – President, CEO & Director Matthew Amigh – Chief Financial Officer
Advertisement
Conference Call Participants
Michael Baker – D.A. Davidson & Co., Research Division Sarang Vora – Telsey Advisory Group LLC Daniel Biolsi – Hedgeye Risk Management, LLC
Advertisement
Presentation
Operator
Greetings, and welcome to the Black Rifle Coffee Company First Quarter 2026 Earnings Call. [Operator Instructions]
As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Matthew McGinley, Vice President of Investor Relations. Thank you. You may begin.
Advertisement
Matthew McGinley Vice President of Investor Relations
Good morning, everyone, and thank you for joining Black Rifle Coffee Company’s First Quarter 2026 Financial Results Conference Call. We released our results yesterday, and the press release and related materials are available on our Investor Relations website at ir.blackriflecoffee.com. Before we begin, I would like to remind you of the company’s safe harbor statement regarding forward-looking statements. During today’s call, management may make forward-looking statements, including guidance and the underlying assumptions. These statements are based on expectations that involve risks and uncertainties, which could cause actual results to differ materially. For a further discussion of these risks, please refer to our previous filings with the SEC. Additionally, this call will include non-GAAP financial measures such as adjusted EBITDA. Whenever we refer to EBITDA, we mean adjusted EBITDA, unless otherwise noted. Reconciliation of non-GAAP measures to the most directly comparable GAAP measures are included in our earnings release, which was furnished to the SEC and is available on our Investor Relations website. Now please refer to the presentation on our Investor Relations website and turn to Slide 4. I would now like to turn the call over to Chris Mondzelewski, CEO of Black Rifle Coffee Company. Monz?
Justine Clowes succeeds Jeremy Orrell at practice with four regional offices
Pictured at SAS Daniels are. front row from left, Paul Tyrer, Nigel Read, Steven Percy; back row from left: Helen Kelly, Justine Clowes(Image: SAS Daniels)
Law firm SAS Daniels has named a new managing partner as part of a “significant transition in its senior leadership team”.
Justine Clowes, deputy CEO and joint head of the Macclesfield office, has succeeded Jeremy Orrell as managing partner at the firm. Meanwhile Nigel Read, head of property and joint head of the Macclesfield office, becomes senior partner.
Mr Orrell, who left the practice on April 30, qualified as a solicitor in 1983 and joined SAS Daniels in 2009. He has led the business since 2017 and has overseen growth across the practice as well as capital investments across its offices in Stockport, Chester, Macclesfield and Congleton. As a corporate lawyer, he has worked on more than 1,000 deals.
Justine Clowes said: “I am delighted to step into the role of managing partner at such an exciting time for our firm. Having worked closely with Jeremy and our talented team for many years, I am committed to building upon our strong foundations of legal excellence and client-focused service. I look forward to leading SAS Daniels into its next chapter of growth and innovation across the North West, as we look to recruit into all our legal departments and grow each of our offices.”
Advertisement
Well-known lawyer Kaye Whitby, partner and head of the SAS Daniels Chester office, is also leaving the firm.
Ms Clowes said: “On behalf of the entire team, I want to express our deepest gratitude to Jeremy and Kaye for their incredible commitment and many years of service. Jeremy’s leadership has been instrumental in our growth. We wish both Kaye and Jeremy the very best for the future.”
Her predecessor Mr Orrell said: “It has been a privilege to lead SAS Daniels and witness our collective growth over the years. I am incredibly proud of the legacy we’ve built and the exceptional talent within our firm. I wish the new board and wider team every future success.”
Three long-standing senior team members at SAS Daniels have been promoted to equity partners: Helen Kelly, partner, head of private client, and joint head of the Stockport office; Steven Percy, partner and head of commercial property; and Paul Tyrer, partner and joint head of the Congleton office. Mr Tyrer will also become head of corporate, a position previously held by Mr Orrell.
Advertisement
SAS Daniels now has 22 partners and a 120-strong specialist team.
To find all the planning applications, traffic diversions, road layout changes, alcohol licence applications and more in your community, visit the Public Notices Portal.
Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
Fox News senior strategic analyst Gen. Jack Keane (ret.) joins ‘Mornings with Maria’ to break down Iran tensions, warn combat may resume and assess President Donald Trump’s push to reopen the Strait of Hormuz after attacks on U.S. forces.
The prospect of renewed conflict in the Middle East is intensifying as tensions escalate in the Strait of Hormuz, with military leaders warning that a return to sustained combat operations may be unavoidable following reported ceasefire violations by Iran.
Fox News senior strategic analyst, retired Gen. Jack Keane, joined FOX Business’ Cheryl Casone on “Mornings with Maria” to discuss the growing risks of escalation, as U.S. forces work to maintain open shipping lanes and protect commercial vessels in one of the world’s most critical energy passageways.
U.S. Navy in transit in the Strait of Hormuz. (Zachary Pearson/U.S. Navy)
Keane pointed to recent Iranian actions, including reported attacks on U.S. and allied assets, as a turning point that could push the situation back into active conflict. Those developments come as the U.S. continues a large-scale operation to secure the Strait of Hormuz.
Rep. Russell Fry, R-S.C., discusses President Donald Trump’s Iran strategy, Myrtle Beach airport disruptions and the economic shift pushing workers to leave high-cost cities on ‘Mornings with Maria.’
“There are two things that will likely force us to go back into combat operations… Fire on U.S. warships, that has happened, and also fire on our allies and partners in the region… That has happened as well,” Keane said.
The retired general emphasized that the current U.S. posture remains defensive, focused on ensuring safe passage for vessels while countering incoming threats ranging from drones to fast boats. At the same time, he underscored that Iran, not the U.S., initiated the latest round of hostilities.
Former Trump deputy national security advisor KT McFarland discusses the launch of ‘Project Freedom’ to guide stranded ships out of the Strait of Hormuz on ‘The Bottom Line.’
“It is Iran who broke the ceasefire by firing at the ships… firing at U.S. warships… they violated the ceasefire, and we’re completely justified in responding to that,” Keane said.
You must be logged in to post a comment Login